Aptevo Therapeutics Announces the Closing of $2.1M Registered Direct Offering

Aptevo Therapeutics, a biotech company developing new cancer treatments, raised approximately $2.1M through a stock and warrant sale. Aptevo intends to use the net proceeds from the proposed offering for the continued clinical development of its product candidates, working capital, and other general corporate purposes.